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Anti-MAG demyelinating neuropathy is diﬃcult to treat. All immunotherapies have failed
except for rituximab, a chimeric B-cell–depleting monoclonal antibody against CD20, that
helps up to 40% of patients based on 2 controlled and several uncontrolled series.1–3 Because
the majority of these patients are left disabled, stronger anti–B-cell agents might be promising.
We describe clinical response and autoantibody changes after treatment with obinutuzumab
(Gazyva), a new generation of humanized anti-CD20 monoclonal antibodies, in 2 patients with
anti-MAG neuropathy who continued to worsen despite multiple courses of rituximab. Obi-
nutuzumab, approved for chronic lymphocytic leukemia (CLL), exerts greater peripheral and
lymphoid B-cell depletion4 and might be more eﬀective in rituximab-refractory patients.
Classiﬁcation of evidence
This is a single observational study without controls and provides Class IV evidence that
obinutuzumab is safe to use in patients with IgM anti-MAG demyelinating neuropathy.
Patients and treatments
Patient 1
A 71-year-old man developed feet paresthesias that progressed in 4 years to bilateral foot drop.
Workup revealed distal demyelinating neuropathy, a benign IgMκ monoclonal gammopathy,
elevated IgM levels, and high-titer anti-MAG antibodies (table). The gammopathy was benign
including normal bone marrow biopsy. He received 3 monthly courses of IVIG without ben-
eﬁts. Rituximab, 2 g, was ineﬀective without aﬀecting the IgM level or anti-MAG titers while his
weakness continued to worsen. Obinutuzumab was then administered in 6 cycles over 6
months, as per the CLL protocol, as follows: day 1: 100 mg; day 2: 900 mg; days 8 and 18:
1,000 mg each; and 1,000 mg thereafter monthly for 5 months.
Patient 2
A 65-year-old man, developed distal leg numbness and paresthesias 13 years ago following
successful therapy for colorectal cancer. The neuropathic symptoms gradually worsened with
sensory ataxia and muscle weakness. Workup revealed a demyelinating neuropathy, an IgMκ
gammopathy, normal bone marrow biopsy, and high-titer anti-MAG antibodies (table). His
symptoms transiently improved with oral corticosteroids and IVIG. Over the following 7 years,
he received 5 courses of rituximab, 2 g every year. His gait and stamina improved after the ﬁrst 2
treatments, but there was no further beneﬁt. He gradually progressed with more weakness,
requiring MAFOs and canes for ambulation, and prominent hand tremors. The IgMκ spike and
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high anti-MAG antibody titers persisted. Because of severe
disease worsening and continuing disability not responding
anymore to rituximab, he was treated with obinutuzumab,
administered for 6 months as described above.
Results
There was no clinical improvement or worsening in the
patients’ neuropathic symptoms 6 and 12 months after
treatment with obinutuzumab. In patient 1, the neurologic
deﬁcits remained unchanged several months after therapy.
Patient 2, 1 year after therapy, showed signs of progression
in pace consistent with his pretreatment course; no accel-
erated worsening related to obinutuzumab was observed.
Both patients tolerated the treatment well. Except for
transient mild thrombocytopenia, there were no compli-
cations during the administration or the follow-up period.
Despite no clinical beneﬁts, however, the IgM levels normal-
ized and remained normal up to a year after obinutuzumab in
both patients (table). Of interest, the anti-MAG antibody titers,
6 months after treatments, were also normalized and remained
low up to 12 months; the IgMκ spike, however, remained
unchanged without discernible diﬀerences in the light chain
(table). In patient 2, 1 year after obinutuzumab, the anti-MAG
titers started to rise, reaching now >70,000 units.
Discussion
The clinical success of ﬁrst-generation glycoengineered type-I,
anti–CD20-mediated, B-cell–depleting, monoclonal antibodies
in autoimmune neurologic and rheumatological disorders has
provided the rationale for using more potent next-generation
anti-CD20 agents. For example, ocrelizumab and ofatumumab
seemmore eﬀective than rituximab in progressive and relapsing
MS.5,6 Obinutuzumab, a third-generation, glycoengineered
type-II, humanized anti-CD20 monoclonal antibody approved
for CLL, has increased binding aﬃnity to the Fc receptor on
B cells and enhanced complement and antibody-dependent
cytotoxicity resulting in extensive B-cell lysis of peripheral
B cells, including some within the lymphoid tissues; because it
also aﬀects IL-6 production, it is expected to cause more sus-
tained depletion of memory B cells and aﬀect antibody pro-
duction. These eﬀects prompted us to evaluate its eﬃcacy in
patients with rituximab-refractory anti-MAG–mediated neu-
ropathy.3 Obinutuzumab, administered for 6 months, was safe
but did not improve the patients’ symptomatology even up to
a year of follow-up. In contrast to rituximab, however, it nor-
malized the IgM level and anti-MAG antibody titers (table).
This observation suggests an eﬀect beyond B-cell depletion;
B cells play a key role in antigen presentation, complement
activation, and cytokine production, such as IL-1, IL-6, and IL-
10, that aﬀect immunoregulatory B and T cells and antibody
production by plasma cells.7 These preliminary results, even in
a limited number of 2 patients, suggest that the IgM anti-MAG
antibodies, despite being pathogenic,8 do not seem to correlate
with clinical response. Whether this is related to our patients’
advanced disease and severe axonal degeneration or to in-
eﬀectiveness of obinutuzumab is unclear. The good tolerance
of the drug, however, the more profound induction of B-cell
depletion, and eﬀect on antibodies, as demonstrated with
normalization of IgM and anti-MAG titers, suggest that obi-
nutuzumab might still be considered as an early treatment of
this diﬃcult-to-treat neuropathy.
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Table IgM levels andanti-MAGantibody titers before and after treatmentwith obinutuzumab in 2 patientswith anti-MAG
neuropathy
Patients
IgM levels
(normal 40–230 mg/dL)
IgM monoclonal
spike
Anti-MAG titers by EIA
(normal ≤ 1:1600 units)
Patient 1
Before obinutuzumab 524 mg/dL Present >1:102,400
After obinutuzumab 229 mg/dL Present <1:1,600 (normalized)
Patient 2
Before obinutuzumab 420 mg/dL Present >1:102,400
After obinutuzumab 173 mg/dL Present <1:1,600 (normalized)
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